含雄黄复方制剂中可溶性砷的研究  

Study of soluble arsenic from prescription containing REALGAR

作　　者：刘冬英[1] 谭倩[2] 白研[1] 梁小红[1] 

机构地区：[1]广东药学院公共卫生学院营养与食品卫生学系,广州510310 [2]肇庆市疾病预防控制中心检验科,526060

出　　处：《国际医药卫生导报》2014年第11期1484-1487,共4页International Medicine and Health Guidance News

基　　金：广东省中医药管理局项目（20131251）

摘　　要：目的测定雄黄复方制剂在人工胃液中可溶性砷的含量，探讨可能被人体日摄入的可溶性砷盐含量，为指导雄黄复方制剂临床合理用药提供科学依据。方法采用原子荧光光谱法、人工胃液提取对11种雄黄复方制剂的可溶性砷盐含量进行测定。结果人工胃液中的可溶性砷盐含量可能和处方有关，本次抽检的样品绝大部分日最高摄取可溶性砷盐量均未超出安全限量。结论雄黄复方制剂中雄黄含量高、日摄取量超出安全限量并不能说明其毒性大，对日服药量较高的雄黄复方制剂的毒性成分可溶性砷盐应进行定量研究。Objective To detect soluble arsenic in prescription containing REALGAR in simulated gastric juice, to discuss human daily intake of soluble arsenic, and to provide a scientific basis for clinical rational drug use of prescription containing REALGAR. Method Extracted by simulated gastric juice and Atomic Fluorescence Spectroscopy. Results Soluble arsenic content in simulated gastric juice maybe relate to prescription. The highest soluble arsenic salt intake of most of the random sample did not exceed safety limit. Conclusions A high content of REALGAR in prescription containing REALGAR and daily intake beyond safety limit do not tell their toxicity, Medication for a high percentage of prescription containing REALGAR of toxic components as soluble arsenic should carry on quantitative research.

关 键 词：雄黄复方制剂 可溶性砷盐 

分 类 号：R285.5[医药卫生—中药学]